Pamidronic acid
- Generic Name
- Pamidronic acid
- Brand Names
- Pamisol
- Drug Type
- Small Molecule
- Chemical Formula
- C3H11NO7P2
- CAS Number
- 40391-99-9
- Unique Ingredient Identifier
- OYY3447OMC
- Background
Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are ...
- Indication
Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.
- Associated Conditions
- Hypercalcemia of Malignancy, Osteolytic lesion, Paget’s Disease, Osteolytic Bone metastases
- Associated Therapies
- -
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
- Conditions
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 263
- Registration Number
- NCT02721433
- Locations
- 🇨🇦
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression
- First Posted Date
- 2014-12-10
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- Bnai Zion Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02313727
- Locations
- 🇮🇱
Bnai Zion Medical Center, Haifa, Israel
Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
- Conditions
- Interventions
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Amgen
- Registration Number
- NCT02101164
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 63
- Registration Number
- NCT02074631
- Locations
- 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 74
- Registration Number
- NCT01907880
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk Disease
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Target Recruit Count
- 48
- Registration Number
- NCT01799616
- Locations
- 🇫🇷
CHU Clermont-Ferrand, Clermont-Ferrand, France
Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial
- First Posted Date
- 2012-11-01
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Tuen Mun Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT01718951
- Locations
- 🇭🇰
Tuen Mun Hospital, Hong Kong, Hong Kong
A Pilot Trial of IV Pamidronate for Low Back Pain
- First Posted Date
- 2010-09-28
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pappagallo, Marco, M.D.
- Target Recruit Count
- 44
- Registration Number
- NCT01210599
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2010-05-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT00738257
- Locations
- 🇬🇧
Novartis Investigative Site, Frimley, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.